<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Avicanna Inc — News on 6ix</title>
<link>https://6ix.com/company/avicanna-inc</link>
<description>Latest news and press releases for Avicanna Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:28:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/avicanna-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835f6c378dffbe2df12fbf8.webp</url>
<title>Avicanna Inc</title>
<link>https://6ix.com/company/avicanna-inc</link>
</image>
<item>
<title>Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-welcomes-initial-us-rescheduling-of-medical-cannabis-and-provides-scientific-update</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-welcomes-initial-us-rescheduling-of-medical-cannabis-and-provides-scientific-update</guid>
<pubDate>Tue, 28 Apr 2026 11:28:00 GMT</pubDate>
<description>Rescheduling aligns with Avicanna&#x2019;s established pharmaceutical and medical cannabis strate...</description>
</item>
<item>
<title>Annual General and Special Meeting of Shareholders to be held May 7, 2026</title>
<link>https://6ix.com/company/avicanna-inc/news/annual-general-and-special-meeting-of-shareholders-to-be-held-may-7-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/annual-general-and-special-meeting-of-shareholders-to-be-held-may-7-2026-1</guid>
<pubDate>Tue, 21 Apr 2026 11:30:00 GMT</pubDate>
<description>TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (&#x201C; Avicanna &#x201D; or the &#x2...</description>
</item>
<item>
<title>Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-agenda-for-6th-annual-clinical-symposium-on-cannabinoid-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-agenda-for-6th-annual-clinical-symposium-on-cannabinoid-therapeutics</guid>
<pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
<description>An established forum for evidence-based clinical discussion, interdisciplinary dialogue, and pati...</description>
</item>
<item>
<title>Avicanna Reports Full Year 2025 Audited Financial Statements</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-reports-full-year-2025-audited-financial-statements</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-reports-full-year-2025-audited-financial-statements</guid>
<pubDate>Wed, 01 Apr 2026 11:30:00 GMT</pubDate>
<description>Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full yea...</description>
</item>
<item>
<title>Avicanna Subsidiary SMGH Completes First Commercial Export to Australia</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-subsidiary-smgh-completes-first-commercial-export-to-australia</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-subsidiary-smgh-completes-first-commercial-export-to-australia</guid>
<pubDate>Thu, 26 Mar 2026 11:30:00 GMT</pubDate>
<description>This marks the first commercial export of organic certified flower for SMGH&#xA0; The export re...</description>
</item>
<item>
<title>Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-sponsorship-of-university-of-calgary-thc-dose-finding-clinical-trial</guid>
<pubDate>Mon, 16 Mar 2026 11:30:00 GMT</pubDate>
<description>TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (&#x201C;Avicanna&#x201D; or the &#x201...</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing</title>
<link>https://6ix.com/company/avicanna-inc/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-5</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-5</guid>
<pubDate>Fri, 13 Mar 2026 12:35:00 GMT</pubDate>
<description>NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietar...</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th</title>
<link>https://6ix.com/company/avicanna-inc/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th</guid>
<pubDate>Tue, 10 Mar 2026 14:21:44 GMT</pubDate>
<description>NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietar...</description>
</item>
<item>
<title>Avicanna Announces Closing of Non-Brokered Private Placement</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-closing-non-brokered-223000974</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-closing-non-brokered-223000974</guid>
<pubDate>Tue, 10 Feb 2026 22:30:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has close</description>
</item>
<item>
<title>Avicanna Announces Medical Cannabis Real World Evidence Results and Publication</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-medical-cannabis-real-122900510</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-medical-cannabis-real-122900510</guid>
<pubDate>Fri, 30 Jan 2026 12:29:00 GMT</pubDate>
<description>Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of PainTORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the pub</description>
</item>
<item>
<title>Avicanna Announces Changes to its Board of Directors</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-changes-board-directors-123000526</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-changes-board-directors-123000526</guid>
<pubDate>Tue, 23 Dec 2025 12:30:00 GMT</pubDate>
<description>TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces Mr. Paul Fornazzari’s resignation from the Company’s board of directors, and is pleased to announce the appointment of Mr. Michael Kott to its board of directors. Michael Kott will join the board January 1, 2026, is an experienced</description>
</item>
<item>
<title>Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-applauds-president-trump-executive-123000384</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-applauds-president-trump-executive-123000384</guid>
<pubDate>Fri, 19 Dec 2025 12:30:00 GMT</pubDate>
<description>Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna’s 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products applauds President Trump’s executive order directing the re</description>
</item>
<item>
<title>Avicanna Applauds President Trump's Executive Order to Reclassify Cannabis & Provides Scientific Update</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-applauds-president-trumps-executive-order-to-reclassify-cannabis-and-provides-scientific-update</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-applauds-president-trumps-executive-order-to-reclassify-cannabis-and-provides-scientific-update</guid>
<pubDate>Fri, 19 Dec 2025 12:30:00 GMT</pubDate>
<description>Avicanna&#x2019;s evidence-based pathway for cannabinoid-based medicine aligns with the executive...</description>
</item>
<item>
<title>Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-pre-clinical-data-123000029</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-pre-clinical-data-123000029</guid>
<pubDate>Wed, 19 Nov 2025 12:30:00 GMT</pubDate>
<description>PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in preclinical studies Provisional patent application on the novel drug delivery platform which can be loaded into products such as tablets, capsules, sachets and pouches TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercializ</description>
</item>
<item>
<title>Avicanna Reports Q3 2025</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-reports-q3-2025-223000704</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-reports-q3-2025-223000704</guid>
<pubDate>Fri, 14 Nov 2025 22:30:00 GMT</pubDate>
<description>TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025. Management Commentary: “Q3 reflects the continued progress of our strategy to build a diversified and sustainable biopharmaceutical business. We are pleased with the impact of our medi</description>
</item>
<item>
<title>Avicanna Announces Change in CFO</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-change-cfo-220000805</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-change-cfo-220000805</guid>
<pubDate>Fri, 12 Sep 2025 22:00:00 GMT</pubDate>
<description>TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products, is pleased to announce Nick Hilborn, CPA, CA, Vice President of Finance, is appointed Interim Chief Financial Officer, following Phillip Cardella, CPA, CA, transition to consultant effective Monday, September 15, 2025. “We thank Phil fo</description>
</item>
<item>
<title>Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-subsidiary-completes-export-cbd-113000203</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-subsidiary-completes-export-cbd-113000203</guid>
<pubDate>Wed, 03 Sep 2025 11:30:00 GMT</pubDate>
<description>This marks the first export of organic certified flower for SMGH, 20th international market for Aureus branded products and 23rd market for all Avicanna products TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority-owned subsidiary Santa Marta</description>
</item>
<item>
<title>Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-latam-sas-teams-harrington-113000788</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-latam-sas-teams-harrington-113000788</guid>
<pubDate>Tue, 02 Sep 2025 11:30:00 GMT</pubDate>
<description>re+PLAY is a CBD wellness brand founded by NBA veteran Al Harrington with products utilizing Avicanna’s patented and proprietary CBD formulations. The initial launch of re+PLAY in the United States includes two products available at Harrington Wellness’ replaycbd.com as well as select retailers across the United States in September. SANTA MARTA, Colombia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Avicanna LATAM SAS is an international biopharmaceutical company based in Colombia and focused on the devel</description>
</item>
<item>
<title>Avicanna Reports Q2 2025</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-reports-q2-2025-114000544</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-reports-q2-2025-114000544</guid>
<pubDate>Thu, 14 Aug 2025 11:40:00 GMT</pubDate>
<description>TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q2 2025. Management Commentary: “Q2 marked another milestone in Avicanna’s journey, fueled by advancements in our pipeline and deeper engagement with the Canadian medical community. In Canada,</description>
</item>
<item>
<title>Avicanna Announces US Patent and Trademark Office Issuance of New Patent</title>
<link>https://6ix.com/company/avicanna-inc/news/avicanna-announces-us-patent-trademark-113000887</link>
<guid isPermaLink="true">https://6ix.com/company/avicanna-inc/news/avicanna-announces-us-patent-trademark-113000887</guid>
<pubDate>Mon, 11 Aug 2025 11:30:00 GMT</pubDate>
<description>USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the USPTO has issued a patent covering Avicanna’s topical cannabinoid compositions for clear skin. The issued patent,</description>
</item>
</channel>
</rss>